Claims

1. Mesenchymal stem cells expressing HLA-A2 on a surface thereof for use in therapy.

2. Use of mesenchymal stem cells expressing HLA-A2 on a surface thereof in the manufacture of a medicament for the prevention or treatment of an inflammatory disease.

3. The mesenchymal stem cells expressing HLA-A2 on a surface thereof of claim 1 or the use of mesenchymal stem cells expressing HLA-A2 on a surface thereof as claimed in claim 2 wherein the mesenchymal stem cells express HLA-A2 at a level of 70% or higher.

4. The mesenchymal stem cells expressing HLA-A2 on a surface thereof of claim 1 or the use of mesenchymal stem cells expressing HLA-A2 on a surface thereof as claimed in claim 2 wherein on the surface thereof, the mesenchymal stem cells express any one selected from the group consisting of CD73, CD90, CD105, CD166, and combinations thereof, and do not express any one selected from the group consisting of CD14, CD34, CD45, HLA-DR, and combinations thereof.

5. The mesenchymal stem cells expressing HLA-A2 on a surface thereof of claim 1 or the use of mesenchymal stem cells expressing HLA-A2 on a surface thereof as claimed in claim 2 wherein on the surface thereof, the mesenchymal stem cells express each of CD73, CD90, CD105, and CD166 at a level of 70% or higher, and express each of CD14, CD34, CD45, and HLA-DR at a level of 1% or lower.

6. The mesenchymal stem cells expressing HLA-A2 on a surface thereof of claim 1 or the use of mesenchymal stem cells expressing HLA-A2 on a surface thereof as claimed in claim 2 wherein on the surface thereof, the mesenchymal stem cells express HLA-A2 at a level of 75% or higher, express each of CD73, CD90, CD105, and CD166 at a level of 70% or higher, and express each of CD14, CD34, CD45, and HLA-DR at a level of 1% or lower.

7. The mesenchymal stem cells expressing HLA-A2 on a surface thereof of claim 1 or the use of mesenchymal stem cells expressing HLA-A2 on a surface thereof as claimed in claim 2 wherein the mesenchymal stem cells are derived from umbilical cord blood.

8. The use of mesenchymal stem cells expressing HLA-A2 on a surface thereof as claimed in claim 2 wherein the inflammatory disease is rheumatoid arthritis, atopy, asthma, allergic rhinitis, Alzheimer's disease, graft versus host disease (GVHD), diabetic nephropathy, Crohn's disease, inflammatory bowel disease, rejection after transplantation, bronchopulmonary dysplasia (BPD), or chronic obstructive pulmonary disease (COPD).